This study aims to evaluate whether, in our setting, it is possible to administer two sessions of high-dose-rate (HDR) brachytherapy per week without significantly raising the incidence of acute toxicities compared to the standard regimen.

Comparison of toxicities and locoregional control between two high dose rate intracavitary brachytherapy regimens in the patients receiving curative treatment for carcinoma cervix: A Randomised controlled trial - NIL

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2025/09/095262

Enrollment

102

Registered

2025-09-22

Start date

Unknown

Completion date

Unknown

Last updated

2025-10-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: C539- Malignant neoplasm of cervix uteri, unspecified

Interventions

Intervention1: Conventional Arm: Receiving sessions of HDR ICB, one session per week. Interval between two sessions will remain one week. Control Intervention1: Study Arm: Receiving sessions of HDR I

Eligibility

Inclusion criteria

Inclusion criteria: KPS a more than 70 Stage IB2 to IVA Baseline blood investigation are within normal limit. No previous treatment for the same.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
to compare acute as well as late bowel and bladder toxicities between the 2 regimens.Timepoint: At first follow up which is at 8 weeks	—

Secondary

Measure	Time frame
To compare loco regional control between the two regimensTimepoint: At first follow up at 8 weeks, at second follow up at 16 weeks & at third follow up at 24 weeks	—

Countries

India

Contacts

Public ContactDr Ankita Prusty

IGMC SHIMLA

drsiddharthvats@gmail.com

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026